Category Archives: Press Release

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

...

Portage Biotech Issues Letter to Shareholders

...

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

...

Portage Biotech Added to Russell 2000® Index

...

Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares

...

Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares

...

Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics’ IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting

...

Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange

...

Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors

...